Last reviewed · How we verify
ODM-212
At a glance
| Generic name | ODM-212 |
|---|---|
| Sponsor | Orion Corporation, Orion Pharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |